A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

J. W. Neal; N. A. Pennell; B. W. Goodgame; M. Lanuti; R. S. Heist; A. T. Shaw; J. S. Temel; P. A. Janne; C. G. Azzoli; L. V. Sequist

doi:10.1200/jco.2010.28.15_suppl.7078

A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7078 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7078-7078 ◽

Cited By ~ 5

Author(s):

J. W. Neal ◽

N. A. Pennell ◽

B. W. Goodgame ◽

M. Lanuti ◽

R. S. Heist ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Toxicity Evaluation ◽

Multicenter Phase ◽

Epidermal Growth

Download Full-text

Phase II trial of paclitaxel-carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non-small cell lung cancer

Thoracic Cancer ◽

10.1111/1759-7714.12074 ◽

2014 ◽

Vol 5 (2) ◽

pp. 149-154 ◽

Cited By ~ 2

Author(s):

Jianliang Yang ◽

Yuankai Shi ◽

Xiangru Zhang ◽

Jianping Xu ◽

Bin Wang ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Phase Ii Trial ◽

Receptor Gene ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Mutation Status ◽

Epidermal Growth

Download Full-text

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2307-6 ◽

2013 ◽

Vol 72 (6) ◽

pp. 1299-1304 ◽

Cited By ~ 10

Author(s):

Kohei Motoshima ◽

Yoichi Nakamura ◽

Kazumi Sano ◽

Yoji Ikegami ◽

Takaya Ikeda ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth

Download Full-text

P8‐62: A phase II trial of osimertinib for elderly patients with epidermal growth factor receptor T790M‐positive non‐small cell lung cancer that progressed during previous treatment

Respirology ◽

10.1111/resp.14150_574 ◽

2021 ◽

Vol 26 (S3) ◽

pp. 311-312

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Previous Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth

Download Full-text

First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7561 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7561-7561 ◽

Cited By ~ 6

Author(s):

Y. Minegishi ◽

M. Maemondo ◽

S. Okinaga ◽

N. Morikawa ◽

A. Inoue ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Lung Cancer Patients ◽

Multicenter Phase ◽

Epidermal Growth

Download Full-text

The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps209 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS209-TPS209 ◽

Cited By ~ 4

Author(s):

N. A. Pennell ◽

J. W. Neal ◽

R. Govindan ◽

P. A. Janne ◽

T. L. Evans ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Early Stage ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Multicenter Phase ◽

Epidermal Growth ◽

Select Trial

Download Full-text

Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)

Clinical Lung Cancer ◽

10.1016/j.cllc.2019.02.016 ◽

2019 ◽

Vol 20 (3) ◽

pp. e402-e406 ◽

Cited By ~ 3

Author(s):

Osamu Hiranuma ◽

Junji Uchino ◽

Tadaaki Yamada ◽

Yusuke Chihara ◽

Nobuyo Tamiya ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Pericardial Effusion ◽

Epidermal Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth

Download Full-text

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181eba657 ◽

2010 ◽

Vol 5 (9) ◽

pp. 1382-1390 ◽

Cited By ~ 80

Author(s):

Neal Ready ◽

Pasi A. Jänne ◽

Jeffrey Bogart ◽

Thomas DiPetrillo ◽

Jennifer Garst ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Group B ◽

Leukemia Group

Download Full-text

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial

The Oncologist ◽

10.1634/theoncologist.2019-0003 ◽

2019 ◽

Vol 24 (5) ◽

pp. 593 ◽

Cited By ~ 4

Author(s):

Akira Nakao ◽

Osamu Hiranuma ◽

Junji Uchino ◽

Chikara Sakaguchi ◽

Toshiyuki Kita ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Elderly Patients ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth

Download Full-text

Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8089 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8089-8089

Author(s):

M. L. Maitland ◽

K. E. Kasza ◽

M. E. Lacouture ◽

W. Liu ◽

K. Soltani ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Inhibition ◽

Epidermal Growth

Download Full-text

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8088 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8088-8088 ◽

Cited By ~ 1

Author(s):

Joel W. Neal ◽

Heather A. Wakelee ◽

Josephine Louella Feliciano ◽

Sarah B. Goldberg ◽

Daniel Morgensztern ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

Egfr Mutant

Download Full-text